Ocular Therapeutix CFO Donald Notman takes temporary medical leave; Jason Robins appointed interim CFO

OCULAR THERAPEUTIX, INC

Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.
Robins granted option to purchase 33,000 shares at $11.45/share, vesting monthly over four years.
Robins, age 49, was SVP Finance since Jan 2025; previously VP Finance at Fusion Pharmaceuticals (acquired by AstraZeneca).
No family relationships or related party transactions with Robins; standard indemnification agreement executed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.